Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

German Medtechs Search For Blue Skies Amid ‘Cloudy Outlook’ For Industry − Medica 2023

Regulatory compliance is no longer the only pressing issue for medtechs in Germany

Executive Summary

While revenues are looking healthier at last, a host of issues in the post-COVID readjustment phase still weigh heavily on medtech manufacturers in Germany, chief among which is EU and national over-regulation. Hospital reform and the digital shift are also on a long list of priority issues to monitor and tackle if Germany’s industrial base is to remain preeminent, said BVMed chief executive Marc-Pierre Möll.

You may also be interested in...



MDR Is The ‘Mother Of European Industry’s Problems’ − Germany's BVMed At Medica 2023

Higher logistics and energy costs are putting medtech P&Ls under pressure, and compliance with the EU MDR is draining any remaining surplus. Sustainability compliance is another cost to factor in, says BVMed chief executive Marc-Pierre Möll in part 2 of his interview with Medtech Insight at Medica 2023. 

German-Speaking European Associations Collaborate To Focus On Medtech’s Needs

Three central European industry associations have agreed to develop joint initiatives and form a collective voice with which to lobby decision-makers on medtech themes of mutual interest.

Resilience And ‘Lessons Learned’ Must Be The COVID Legacy In Germany

The COVID-19 threat is abating and control measures are easing, but government commitments made at the height of the pandemic to forearm against future health care emergencies should not be abandoned. That is the position of both the German Advisory Council on Health and Care and the IVD industry.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT148501

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel